title: Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer.
abstract: Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody (mAb) directed against an extracellular region of the human epidermal growth-factor receptor type 2 (HER2) protein. We hypothesized that a single adeno-associated virus (AAV)-mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long-term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. The adeno-associated virus gene transfer vector AAVrh.10alphaHER2 was constructed based on a non-human primate AAV serotype rh.10 to express the complementary DNAs for the heavy and light chains of mAb 4D5, the murine precursor to trastuzumab. The data show that genetically transferred anti-HER2 selectively bound human HER2 protein and suppressed the proliferation of HER2(+) tumor cell lines. A single administration of AAVrh.10alphaHER2 provided long-term therapeutic levels of anti-HER2 antibody expression without inducing an anti-idiotype response, suppressed the growth of HER2(+) tumors and increased the survival of tumor bearing mice. In the context that trastuzumab therapy requires frequent and repeated administration, this strategy might be developed as an alternate platform for delivery of anti-HER2 therapy.
authors.affiliation: Department of Genetic Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
authors.forename: G
authors.initials: G
authors.lastname: Wang
authors.forename: J
authors.initials: J
authors.lastname: Qiu
authors.forename: R
authors.initials: R
authors.lastname: Wang
authors.forename: A
authors.initials: A
authors.lastname: Krause
authors.forename: J L
authors.initials: JL
authors.lastname: Boyer
authors.forename: N R
authors.initials: NR
authors.lastname: Hackett
authors.forename: R G
authors.initials: RG
authors.lastname: Crystal
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology; D000918:Antibody Specificity; D048708:Cell Growth Processes / Q000276:immunology; D045744:Cell Line, Tumor; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology*; D019076:Transgenes; D023041:Xenograft Model Antitumor Assays
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
references.citation: Immunol Rev. 2008 Apr;222:9-27
references.pmid: 18363992
references.citation: Mol Ther. 2006 Jan;13(1):67-76
references.pmid: 16260185
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1562-8
references.pmid: 18524844
references.citation: Am J Respir Cell Mol Biol. 1993 Oct;9(4):448-54
references.pmid: 8104437
references.citation: Cancer Res. 2003 Jun 15;63(12):3257-62
references.pmid: 12810656
references.citation: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
references.pmid: 1350088
references.citation: Curr Opin Mol Ther. 2000 Aug;2(4):376-82
references.pmid: 11249767
references.citation: Gene Ther. 2006 Oct;13(19):1391-402
references.pmid: 16724093
references.citation: Hum Gene Ther. 2009 Mar;20(3):267-81
references.pmid: 19257851
references.citation: Cancer Res. 1998 Jul 1;58(13):2825-31
references.pmid: 9661897
references.citation: J Immunol Methods. 2007 Jan 10;318(1-2):113-24
references.pmid: 17161420
references.citation: J Clin Invest. 1995 Dec;96(6):2980-9
references.pmid: 8675670
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Cancer Res. 1990 Mar 1;50(5):1550-8
references.pmid: 1689212
references.citation: Nature. 1984 Dec 6-12;312(5994):513-6
references.pmid: 6095109
references.citation: Oncogene. 1998 Oct 29;17(17):2235-49
references.pmid: 9811454
references.citation: Oncogene. 2007 May 28;26(25):3637-43
references.pmid: 17530017
references.citation: Cancer Gene Ther. 2009 Feb;16(2):184-94
references.pmid: 18758433
references.citation: Clin Cancer Res. 2002 Jun;8(6):1720-30
references.pmid: 12060609
references.citation: Appl Microbiol Biotechnol. 2007 Mar;74(4):723-9
references.pmid: 17225094
references.citation: J Immunol. 2004 Jul 1;173(1):61-7
references.pmid: 15210759
references.citation: Clin Cancer Res. 2001 Oct;7(10):3239-50
references.pmid: 11595720
references.citation: Cancer Genet Cytogenet. 2003 Mar;141(2):138-42
references.pmid: 12606131
references.citation: J Immunol. 2007 Jun 1;178(11):7120-31
references.pmid: 17513761
references.citation: Nat Biotechnol. 2005 May;23(5):551-2
references.pmid: 15877069
references.citation: Oncogene. 1999 Apr 1;18(13):2241-51
references.pmid: 10327070
references.citation: Scand J Immunol. 2008 Jul;68(1):58-66
references.pmid: 18482206
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Oncogene. 1988 Apr;2(4):387-94
references.pmid: 2896329
references.citation: Hum Gene Ther. 2008 Mar;19(3):300-10
references.pmid: 18324912
references.citation: Ann Oncol. 2007 Jun;18(6):977-84
references.pmid: 17229773
references.citation: Nat Biotechnol. 2005 May;23(5):584-90
references.pmid: 15834403
references.citation: J Surg Res. 2008 Jul;148(1):60-6
references.pmid: 18570932
references.citation: Mol Ther. 2000 Apr;1(4):376-82
references.pmid: 10933956
references.citation: J Biosci Bioeng. 2004;98(4):298-303
references.pmid: 16233709
references.citation: Hum Gene Ther. 1997 Jul 1;8(10):1219-29
references.pmid: 9215739
references.citation: Mol Ther. 2009 Feb;17(2):294-301
references.pmid: 19066597
references.citation: Hum Gene Ther. 1999 Sep 20;10(14):2295-305
references.pmid: 10515449
references.citation: Mol Ther. 2004 Sep;10(3):411-6
references.pmid: 15336642
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6179-85
references.pmid: 17062695
references.citation: Endocr Relat Cancer. 2002 Jun;9(2):75-85
references.pmid: 12121832
references.citation: Hum Gene Ther. 2002 Aug 10;13(12):1483-93
references.pmid: 12215269
references.citation: Hum Gene Ther. 1998 Oct 10;9(15):2165-75
references.pmid: 9794201
references.citation: Gene Ther. 1994 Sep;1(5):332-7
references.pmid: 7584099
references.citation: Mol Ther. 2008 Jan;16(1):203-9
references.pmid: 18059375
references.citation: Ann Oncol. 2001;12 Suppl 1:S43-7
references.pmid: 11521721
references.citation: Mol Ther. 2004 Mar;9(3):328-36
references.pmid: 15006599